FGC
SVA

Financial Gravity Companies’s Sinovac Biotech, Ltd SVA Stock Holding History

Financial Gravity Companies’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$0 Buy
+23
New – ﹤0.01% 998
2024
Q4 		$0 Hold
24
– – ﹤0.01% 1033
2024
Q3 		$0 Buy
+24
New – ﹤0.01% 689
2018
Q4 		$3K Buy
+399
New +$2.91K ﹤0.01% 882
2018
Q1 		$1K Sell
135
-10,411
-99% -$85.8K ﹤0.01% 1373
2017
Q4 		$87K Buy
+10,546
New +$78.9K 0.1% 203

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Financial Gravity Companies's SVA Position: Q2 2025 in Review

Financial Gravity Companies opened a new position in Sinovac Biotech, Ltd (SVA) in Q2 2025: 23 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #998 among its holdings. This is a return to the name: Financial Gravity Companies previously reported a position in SVA as recently as Q4 2024.

Financial Gravity Companies first reported a position in SVA in Q4 2017 and has held it in 6 quarters since. The position peaked at $87K in Q4 2017. 28 funds tracked by Wall St. Rank hold SVA as of Q2 2025.

  • Financial Gravity Companies held 23 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2025.
  • Sinovac Biotech, Ltd was a new Financial Gravity Companies position in Q2 2025.
  • Sinovac Biotech, Ltd made up ﹤0.01% of Financial Gravity Companies's portfolio in Q2 2025, its #998 holding.
  • Financial Gravity Companies first reported a position in Sinovac Biotech, Ltd in Q4 2017 and has held it in 6 quarters since.
  • Financial Gravity Companies's Sinovac Biotech, Ltd position peaked at $87K in Q4 2017.
  • 28 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2025.

Based on Financial Gravity Companies's 13F filing for Q2 2025, filed 8 Aug 2025.